Fulcrum Therapeutics, Inc.

FULC · Nasdaq · SIC 2834: Pharmaceutical Preparations
130
SEC Filings

Business Summary

Competition for additional information. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong ...

Next Earnings

Q2 FY2026 — expected 2026-08-23

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionFULCdiscussed_in_filing Cybersecurity
topic_mentionFULCdiscussed_in_filing Cybersecurity
topic_mentionFULCdiscussed_in_filing Regulation
topic_mentionFULCdiscussed_in_filing Regulation

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-242025-12-310001193125-26-065197EDGAR88K words
2025-02-252024-12-310000950170-25-026068EDGAR—
2024-02-272023-12-310000950170-24-021074EDGAR—
2023-03-092022-12-310000950170-23-006841EDGAR—
2022-03-032021-12-310000950170-22-002727EDGAR—
2021-03-042020-12-310001564590-21-010715EDGAR—
2020-03-052019-12-310001564590-20-008951EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-10-292025-09-300001193125-25-254633EDGAR56K words
2025-07-292025-06-300000950170-25-099407EDGAR—
2025-05-012025-03-310000950170-25-061442EDGAR—
2024-11-132024-09-300000950170-24-125931EDGAR—
2024-07-312024-06-300000950170-24-088238EDGAR—
2024-05-132024-03-310000950170-24-058193EDGAR—
2023-11-072023-09-300000950170-23-059755EDGAR—
2023-08-032023-06-300000950170-23-037579EDGAR—
2023-05-152023-03-310000950170-23-021960EDGAR—
2022-11-082022-09-300000950170-22-022913EDGAR—
2022-08-112022-06-300000950170-22-016644EDGAR—
2022-05-092022-03-310000950170-22-008235EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-240001193125-26-065190EDGAR2K words
2026-01-120001193125-26-009845EDGAR—
2025-12-110001193125-25-314728EDGAR—
2025-12-080001193125-25-310509EDGAR—
2025-10-290001193125-25-254619EDGAR—
2025-08-280001193125-25-190746EDGAR—
2025-07-290000950170-25-099404EDGAR—
2025-06-270001193125-25-151276EDGAR—
2025-05-010000950170-25-061439EDGAR—
2025-03-040000950170-25-032355EDGAR—

130 total filings indexed. 101 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001680581
TickerFULC
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 3034a5636a6e29cadce7f45e77b652ff9e7c7c656f549426583d550f27468638
parent: d1354bdffdb632c21f1eed1543518aeaafa8e110cc5c90973dc3e6517b06e6f4
content hash: 0864a59505887ea590c16ab66ee15a59961e2a58dd8248cb88e2e66cfd87510b
signed: 2026-04-13T04:45:10.101Z
sources: 19 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf